Online citations, reference lists, and bibliographies.
← Back to Search

A Phase I Study Of Extrapleural Pneumonectomy And Intracavitary Intraoperative Hyperthermic Cisplatin With Amifostine Cytoprotection For Malignant Pleural Mesothelioma.

L. Zellos, W. Richards, Leah Capalbo, M. Jaklitsch, L. Chirieac, B. Johnson, R. Bueno, D. Sugarbaker
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVE This study was undertaken to determine maximum tolerated dose and toxicity of intraoperative intracavitary hyperthermic cisplatin perfusion with amifostine after extrapleural pneumonectomy for malignant pleural mesothelioma. METHODS Patients with mesothelioma were prospectively enrolled. Those with resectable disease received amifostine and 1-hour hyperthermic cisplatin perfusion of ipsilateral hemithorax and abdomen. Morbidity, recurrence, and survival were recorded. RESULTS Forty-two patients were enrolled; 29 underwent resection (operative mortality 7%, 2/29). Median age was 57 years. Eighteen were in pathologic stage I or II; 11 were in stage III. Median hospitalization was 15 days. Common complications were atrial fibrillation (66%, 19 patients), deep venous thrombosis (31%, 9 patients), and grade 3+ renal toxicity (31%, 9 patients). Feasibility was determined. Renal toxicity was unrelated to cisplatin dose, with no maximum tolerated dose determined. Overall median survival was 17 months (resected 20 months, unresected 10 months). Median survivals were 26 months for patients receiving higher cisplatin doses and 16 months for those receiving lower doses (P = .35). Survival was significantly longer with negative extrapleural nodes (31 vs 14 months, P = .0115) and early stage (all resected 35 months for stage I-II vs 14 months for stage III, P = .0022, epithelial 39 months for stage I-II vs 15 months for stage III, P = .0072). CONCLUSION Early stage and negative extrapleural lymph nodes were associated with prolonged survival. Single-dose amifostine did not protect adequately against cisplatin-induced renal toxicity. Additional cytoprotective strategies are needed to allow determination of cisplatin maximum tolerated dose.
This paper references
Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy.
P. Sugarbaker (2005)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
Innovative therapies : intraoperative intracavitary che
MY Chang (2004)
Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread.
Y. Refaely (2001)
Activation of circulating platelets by hyperthermal stress.
H. Take (1996)
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma.
D. Lardinois (2006)
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer:A Gynecologic Oncology Group study
P. Box (2006)
Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.
P. Ruffié (1989)
Innovative therapies: intraoperative intracavitary chemotherapy.
M. Chang (2004)
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
B. Movsas (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Effects of hyperthermal stress on the fibrinolytic system.
K. Tamura (1996)
Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
D. Betticher (1995)
Intraperitoneal Cisplatin with Intraperitoneal Gemcitabine in Patients with Epithelial Ovarian Cancer
P. Sabbatini (2004)
Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
J. Schiller (1996)
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
M. Hensley (1999)
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
A. Planting (1999)
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
G. Kemp (1996)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
The effects of intentional hyperthermia on the Thrombelastograph and the Sonoclot analyser.
E. Pivalizza (1999)

This paper is referenced by
Hypertherme intrathorakale Chemotherapie in der Thoraxchirurgie
H. Hofmann (2019)
Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.
K. Okabe (2017)
Making the case for molecular staging of malignant pleural mesothelioma.
R. Bueno (2009)
Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
Mbbs Christopher Cao BSc (2011)
Malignant mesothelioma as a difficult interdisciplinary problem
W. Rokicki (2017)
Zytoreduktive Chirurgie und hypertherme intrathorakale Chemotherapieperfusion
H. Hofmann (2010)
Surgical Treatment of Malignant Pleural Mesothelioma
A. Kaufman (2011)
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
Cold-plasma coagulation in the treatment of malignant pleural mesothelioma: results of a combined approach.
M. Hoffmann (2010)
Recent Advances in Surgical Techniques for Multimodality Treatment of Malignant Pleural Mesothelioma
C. Asteriou (2013)
Intraoperative adjuncts for malignant pleural mesothelioma.
W. Chan (2017)
A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma
B. Burt (2018)
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
Extrapleural Pneumonectomy A Blessing or a Curse in the Management of Pleural Malignant Mesothelioma
S. Qadri (2015)
Electrophysiologic Complications in Cancer Patients.
Dae Hyun Lee (2019)
Feasibility trial assessing intrapleural photodynamic therapy combined with pleurectomy/decortication then chemotherapy in malignant pleural mesothelioma patients
S. Mordon (2019)
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience.
M. Ried (2013)
The Evolution of Multimodality Therapy for Malignant Pleural Mesothelioma
M. Zauderer (2011)
Optimized intrapleural cisplatin chemotherapy with a fibrin carrier after extrapleural pneumonectomy: a preclinical study.
I. Opitz (2011)
Multimodality strategies in malignant pleural mesothelioma.
W. Weder (2009)
Mesothelioma: path to multimodality treatment.
S. Su (2009)
Behandlung maligner Tumoren der Pleura
M. Ried (2012)
Pleural malignancies.
Joseph S. Friedberg (2010)
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
WITHDRAWN: Is there life after the Mesothelioma and Radical Surgery trial? Does extrapleural pneumonectomy still have a role in the management of pleural mesothelioma? A 13-year, single-center experience.
S. Qadri (2014)
Clinical outcomes of cytoreductive surgery combined with intrapleural perfusion of hyperthermic chemotherapy in advanced lung adenocarcinoma with pleural dissemination.
Eunjue Yi (2016)
Surgery for malignant pleural mesothelioma
D. Sugarbaker (2010)
The seven attributes of the academic surgeon: Critical aspects of the archetype and contributions to the surgical community.
T. Rosengart (2017)
Genes Associated With Prognosis After Surgery For Malignant Pleural Mesothelioma Promote Tumor Cell Survival In Vitro
G. Gordon (2010)
Intracavitary cisplatin-fibrin chemotherapy after surgery for malignant pleural mesothelioma: A phase I trial.
I. Opitz (2019)
Anwendung der hyperthermen intrathorakalen Chemotherapie (HITHOC) in Deutschland
Michael Ried (2018)
Kombinierte Technik der chirurgischen Zytoreduktion und hyperthermen intrathorakalen Chemotherapieperfusion
M. Ried (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar